Adiponectin analogue - Allysta Pharmaceuticals
Alternative Names: Adiponectin peptide analog - Allysta Pharmaceuticals; ADP 355; ALY 688; ALY 732; ALY-688-SRLatest Information Update: 28 May 2024
At a glance
- Originator Allysta Pharmaceuticals
- Class Anti-inflammatories; Eye disorder therapies; Hepatoprotectants; Peptides
- Mechanism of Action Adiponectin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Dry eyes
- No development reported Non-alcoholic steatohepatitis
Most Recent Events
- 28 May 2024 No recent reports of development identified for phase-I development in Non-alcoholic-steatohepatitis(In volunteers) in Australia (SC, Injection)
- 29 Mar 2023 Allysta Pharmaceutical completes a phase-II/III clinical trials in Dry eyes in USA (Ophthalmic) (NCT04899518)
- 30 Aug 2021 Allysta Pharmaceutical terminates a phase I trial in Non-alcoholic steatohepatitis (In volunteers) in Australia (SC) because inability to recruit due to COVID-19 pandemic restrictions (NCT04855565)